We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $11.41, moving -2.89% from the previous trading session. This move lagged the S&P 500's daily loss of 1.82%. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw a decrease of 2.86%.
Shares of the infectious disease drug developer witnessed a gain of 18.33% over the previous month, beating the performance of the Medical sector with its gain of 5.28%, and the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. It is anticipated that the company will report an EPS of $0.19, marking a 18.75% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.78 per share and revenue of $536.82 million. These totals would mark changes of +30% and +5.22%, respectively, from last year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 15.13. This signifies a discount in comparison to the average Forward P/E of 23.93 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 103, finds itself in the top 42% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $11.41, moving -2.89% from the previous trading session. This move lagged the S&P 500's daily loss of 1.82%. Meanwhile, the Dow experienced a drop of 1.09%, and the technology-dominated Nasdaq saw a decrease of 2.86%.
Shares of the infectious disease drug developer witnessed a gain of 18.33% over the previous month, beating the performance of the Medical sector with its gain of 5.28%, and the S&P 500's gain of 0.71%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. It is anticipated that the company will report an EPS of $0.19, marking a 18.75% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.78 per share and revenue of $536.82 million. These totals would mark changes of +30% and +5.22%, respectively, from last year.
Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
In terms of valuation, Adma Biologics is presently being traded at a Forward P/E ratio of 15.13. This signifies a discount in comparison to the average Forward P/E of 23.93 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 103, finds itself in the top 42% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.